Clinical Trial Update: Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging trial evaluating dronedarone for controlling ventricular rate in Japanese patients with permanent atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Multaq (dronedarone)

Snippet

Sponsor: Sanofi | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED